Frontiers in Systemic Therapy for Unresectable or Metastatic Adrenocortical Carcinoma: Harnessing Novel Therapeutic Approaches.

Adam E Singer, Nikhita Kathuria-Prakash, David Shabsovich, Lizette Garcia, Leland Damron, Allan J Pantuck, Alexandra Drakaki

Abstract readReview

PubMed Full text at PMC Publisher

In one paragraph

Review in Clinical Medicine Insights. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Adam E SingerDivision of Hematology/Oncology, Department of Internal Medicine, University of California, Los Angeles, Los Angeles, CA, USA.ORCID https://orcid.org/0009-0006-5467-9444

Nikhita Kathuria-PrakashDivision of Hematology/Oncology, Department of Internal Medicine, University of California, Los Angeles, Los Angeles, CA, USA.

David ShabsovichDivision of Hematology/Oncology, Department of Internal Medicine, University of California, Los Angeles, Los Angeles, CA, USA.

Lizette GarciaDivision of Hematology/Oncology, Department of Internal Medicine, University of California, Los Angeles, Los Angeles, CA, USA.

Leland DamronDepartment of Internal Medicine, University of California, Los Angeles, Los Angeles, CA, USA.

Allan J PantuckDepartment of Urology, University of California, Los Angeles, Los Angeles, CA, USA.

Alexandra DrakakiDivision of Hematology/Oncology, Department of Internal Medicine, University of California, Los Angeles, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adrenocortical carcinoma is a rare, aggressive endocrine malignancy with limited effective systemic therapy options and an overall poor prognosis for unresectable or metastatic disease. Chemotherapy and mitotane are the traditional systemic therapies of choice. More recently, as drug development in oncology has shifted away from chemotherapy, a host of therapeutic approaches targeting novel mechanisms of action has been studied in adrenocortical carcinoma. This review summarizes all nonchemotherapeutic approaches that have been and/or are currently being tested in clinical trials for the treatment of unresectable or metastatic adrenocortical carcinoma.

Indexed as

Adrenocortical carcinomaimmune checkpoint inhibitorsradiopharmaceuticalssystemic therapytyrosine kinase inhibitors

Identifiers

PMID40893150

DOI10.1177/11795549251364042

PMCPMC12397596

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.